Why merging healthcare organizations should pay attention to AT&T and Time Warner

The last few months in mergers and acquisition (M&A) activity in healthcare have been dominated by massive deals proposed across sectors—like drugstore chain CVS Health wanting to buy health insurer Aetna for $69 billion. What those companies should watch for, writes Morning Consult’s Jon Reid, is the result of the case challenging a merger with similar dynamics: the combination of AT&T and Time Warner.

Like the CVS-Aetna and Cigna-Express Scripts deals, the merger between AT&T and Time Warner would be a vertical integration, not the horizontal mergers the DOJ has fought in recent years like the abandoned combination of insurance giants Anthem and Cigna. If the $85 billion AT&T-Time Warner deal is blocked on antitrust grounds, however, the DOJ’s strategy may change.

“The federal agencies have not litigated a vertical merger case in roughly 40 years,” William Kovacic, a law professor at George Washington University and a Federal Trade Commission member from 2006 to 2011, said to Morning Consult. If the DOJ wins in the AT&T-Time Warner case, “the government will have a more confident basis for challenging other vertical deals in the future,” he said.

So far, however, the DOJ hasn’t challenged any of the recently announced megamergers.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.